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https://doi.org/10.1016/j.celrep.2018.10.046SUMMARY
Multi-region sequencing is used to detect intratumor
genetic heterogeneity (ITGH) in tumors. To assess
whether genuine ITGH can be distinguished from
sequencing artifacts, we performed whole-exome
sequencing (WES) on three anatomically distinct re-
gions of the same tumor with technical replicates to
estimate technical noise. Somatic variants were
detected with three different WES pipelines and
subsequently validated by high-depth amplicon
sequencing. The cancer-only pipelinewas unreliable,
with about 69% of the identified somatic variants be-
ing false positive. Even with matched normal DNA for
which 82% of the somatic variants were detected
reliably, only 36%–78% were found consistently in
technical replicate pairs. Overall, 34%–80% of the
discordant somatic variants, which could be inter-
preted as ITGH, were found to constitute technical
noise. Excluding mutations affecting low-mappabil-
ity regions or occurring in certainmutational contexts
was found to reduce artifacts, yet detection of sub-
clonal mutations by WES in the absence of orthog-
onal validation remains unreliable.
INTRODUCTION
Intratumor genetic heterogeneity (ITGH), typically defined as the
coexistence of genetically distinct but clonally related cancer
cells within the same patient (Yap et al., 2012), canmanifest itself
spatially within the same lesion or as genetic differences be-
tween different metastatic sites and the primary tumor from the
same patient (Ding et al., 2010; Gerlinger et al., 2012; Marusyk1446 Cell Reports 25, 1446–1457, November 6, 2018 ª 2018 The Au
This is an open access article under the CC BY license (http://creativeet al., 2012; Newburger et al., 2013; Yates et al., 2015). The broad
availability of massively parallel sequencing has accelerated
research into ITGH, and numerous studies have applied whole-
exome or targeted-exome sequencing to multiple biopsies
from the same cancer, to different metastatic lesions from the
same patient, and more recently to multiple single cells from
the same cancer (Gerlinger et al., 2012; Hou et al., 2012; Marte-
lotto et al., 2017; Navin et al., 2011; Newburger et al., 2013; Nik-
Zainal et al., 2012; Wang et al., 2014; Xu et al., 2012). ITGH
represents a snapshot of the tumor’s evolutionary path and is
a clinically important phenomenonwith implications in prognosis
and treatment response (Fisher et al., 2013; Hiley et al., 2014;
Jiang et al., 2014;Marusyk et al., 2012;Morris et al., 2016; Turner
and Reis-Filho, 2012).
The assessment of ITGH, by definition, involves the detection
of subclonal, low-frequency variants that are not uniformly pre-
sent in all cancer cells and is made possible by the availability
of bioinformatics tools to detect low-frequency somatic muta-
tions with high sensitivity (Cibulskis et al., 2013; Koboldt et al.,
2012; Saunders et al., 2012; Wilm et al., 2012). However, the
presence of technical noise in sequencing data is well known
(Li, 2014; Nakamura et al., 2011), and it is unclear whether
genuine ITGH can be reliably distinguished from artifacts gener-
ated during library preparation, sequencing, and data process-
ing (Qi et al., 2015; Smith et al., 2014). Understanding the
signal-to-noise characteristics in these experiments is critical
for the interpretation of ITGH.
Given the implications in prognosis and treatment response,
ITGH is an important consideration in the clinical setting.
Because the cost of WES and complex informed consent re-
quirements, the inclusion of matching normal samples still repre-
sents a limitation in the sequencing of tumor samples in some
large clinical trials (Shi et al., 2017). Whether subclonal mutations
can be robustly identified in the absence of matching normal
samples and whether pooled normal samples from unrelatedthor(s).
commons.org/licenses/by/4.0/).
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Figure 1. Reliability of Somatic SNVs and INDELs Detected by WES and High-Depth Amplicon Sequencing Validation of Variants
(A) Biopsies were obtained from three anatomically distinct regions of each tumor to assess spatial genomic heterogeneity. One of the three DNA samples was
split in two to provide a pair of technical replicates. Somatic variants were detected by three different WES analysis pipelines and subsequently validated by high-
depth amplicon sequencing.
(B) Number of somatic mutations identified by WES in each technical replicate, subclassified according to their validation status by high-depth amplicon
sequencing.
(C and D) Concordance of somatic SNVs (C) and INDELs (D) defined in each pair of technical replicates using the matched-normal WES analysis pipeline (left) or
high-depth amplicon sequencing (right). Discordance between the replicates quantified as the Jaccard distance shown next to each bar and the pathogenicity of
variants were assessed as described in Supplemental Experimental Procedures. Putative WES variants re-sequenced with high-depth amplicon sequencing
were further classified as absent (VAF < 1%), germline (tumor VAF/germline VAF < 5), or low depth (<503).
(E) Validation status of variants (SNVs and INDELs) detected byWES in technical replicate pairs, categorized as concordant (‘‘con’’) or discordant (‘‘dis’’) byWES,
and the distribution of their AmpliSeq validation status is shown within each bar.
See also Figure S1.individuals would serve as a reasonable control should be
explored as alternative options for the assessment of ITGH in
the clinical setting.
In this study, we aimed to assess the reliability of somatic
variant detection from whole-exome sequencing (WES) in the
context of ITGH (Figures 1A and S1A). To address this ques-
tion, we performed WES on DNA from biopsies obtained
from three anatomically distinct regions of six primary breast
cancers (6 3 3 biopsies) and from matched peripheral blood
leukocytes. Additionally, to determine the background noise
levels as a comparator for the assessment of ITGH, aliquots
of the same DNA samples from six distinct biopsies were
sequenced twice to generate technical replicates. We exam-
ined the reliability of somatic variant detection using threedifferent analysis approaches, namely, using cancer WES
data only, cancer data and WES from pooled unrelated (i.e.,
non-matched) normal samples, and WES data from cancer
and matching normal tissue (i.e., blood). Each approach used
different sets of detection algorithms and filtering steps in an
attempt to control for the specific biases associated with
each approach. To generate the ‘‘gold standard’’ benchmark
dataset, we re-sequenced all somatic variants identified by
any of the three somatic variant detection pipelines in at least
one sample using high-depth targeted amplicon sequencing.
Given the higher depth obtained by amplicon sequencing, we
assessed true ITGH and estimated the frequency of false pos-
itives by the different detection pipelines. Finally, we evaluated
the sequence patterns and context in which the artifactualCell Reports 25, 1446–1457, November 6, 2018 1447
Table 1. Tumor Characteristics and Estimated Tumor Cellularity
and Ploidy from WES Data Using FACETS
Sample Subtype Stage Grade
Estimated
Purity (%)
Estimated
Ploidy
Case 1 biorep
A/techrep 1
ER+/PR+/
HER2+
IIA 2 53.8 1.92
Case 1 biorep B 46.3 2.00
Case 1 biorep C 26.0 1.92
Case 1 techrep 2 54.0 1.92
Case 2 biorep A ER/PR/
HER2
IIB 3 40.0 2.14
Case 2 biorep
B/techrep 1
32.3 1.79
Case 2 biorep C NE 1.72
Case 2 techrep 2 38.5 2.03
Case 3 biorep A ER+/PR+/
HER2+
IIB 2 56.4 1.89
Case 3 biorep B 72.8 1.93
Case 3 biorep
C/techrep 1
64.9 1.90
Case 3 techrep 2 66.7 1.93
Case 4 biorep A ER+/PR/
HER2
IIB 2 60.4 1.98
Case 4 biorep
B/techrep 1
61.7 1.95
Case 4 biorep C 57.6 1.99
Case 4 techrep 2 57.6 1.94
Case 5 biorep A ER/PR/
HER2
IIA 3 78.7 2.60
Case 5 biorep
B/techrep 1
76.7 2.62
Case 5 biorep C 80.8 2.82
Case 5 techrep 2 76.2 2.61
Case 6 biorep
A/techrep 1
ER+/PR+/
HER2+
IIA 2 47.8 1.99
Case 6 biorep B 49.4 2.05
Case 6 biorep C 52.9 2.18
Case 6 techrep 2 49.0 1.96
biorep, biological replicate; NE, could not be estimated; techrep, tech-
nical replicate; WES, whole-exome sequencing.mutations occurred to improve the specificity of WES for char-
acterizing genuine ITGH.
RESULTS
Limited Reliability of SomaticMutations Defined byWES
We performed WES on DNA extracted from three distinct re-
gions of the primary tumor and the matching normal blood cells
from six breast cancer patients, including four with estrogen re-
ceptor-positive and two with triple-negative cancers (Table 1).
The biopsies were obtained from three anatomically distinct re-
gions of each tumor at least 1 cm apart (i.e., intratumor repli-
cates; Figure 1A) in the context of a prospective institutional
review board-approved study to assess intratumor molecular1448 Cell Reports 25, 1446–1457, November 6, 2018heterogeneity (von Wahlde et al., 2017). All tumor samples had
at least 50% tumor cellularity on the basis of pathologic assess-
ment. For the technical replicates, a second library was gener-
ated from one of the tumor DNA samples randomly selected
from each cancer and sequenced byWES using the same proto-
col at the same facility on a different day. The mean target depth
was 1603 (range 703 to 2203; Table S1), consistent with rec-
ommendations for WES (Clark et al., 2011; Sims et al., 2014).
Following WES, somatic single-nucleotide variants (SNVs) and
small insertion-deletions (INDELs) were identified by three
different somatic variant calling pipelines that used (1) the tumor
DNA alone (i.e., tumor only, a common approach in clinical prac-
tice), (2) tumor DNA and pooled unrelated normal DNA (i.e.,
cohort normal), or (3) tumor DNA and patient-matched normal
DNA (i.e., matched normal; Figure S1A; Supplemental Experi-
mental Procedures). Targeted amplicon sequencing using an
orthogonal library generation and an independent sequencing
method (AmpliSeq) was performed for all putative somatic vari-
ants identified by any of the WES variant calling pipelines on
all tumor and matching normal DNA to a median depth of
6053 to define the ‘‘gold standard’’ mutation status for each
identified somatic variant (Table S1; Supplemental Experimental
Procedures).
To quantify the technical reliability of somatic mutation detec-
tion by the matched-normal WES pipeline, the approach that is
most frequently used in the research setting to assess ITGH,
we compared the somatic mutations identified in the six pairs
of technical replicates. In this experiment, tumor samples and
normal samples were sequenced to a median coverage of
1843 (range 92–211) and 903 (range 80–138), respectively
(Table S1). We identified medians of 74 (range 40–125) and 3
(range 0–13) somatic SNVs and INDELs, respectively, in each
of the 12 DNA samples. Considering the high-depth amplicon
sequencing results as the ‘‘gold standard,’’ we categorized
candidate mutations detected in WES as true somatic, absent,
germline-like (incorporating genuine germline variants and arti-
factual variant alleles caused by alignment biases and/or the
sequencing technology) (Kim and Speed, 2013), or low-depth
(i.e., technical failure with amplicon sequencing; Table S2; Sup-
plemental Experimental Procedures). Excluding the low-depth
(technical failure) variants, a median 82% (range 56%–90% per
sample) of the somatic SNVs were confirmed as somatic, a me-
dian 5% (range 0%–16%) as germline-like, and the remaining
were absent by AmpliSeq (Figure 1B; Table S3).
Given that both technical replicates used the same input DNA,
we anticipated detecting nearly identical somatic mutations in
each pair of replicates. However, only a subset of the somatic
SNVs and INDELs were consistently identified in technical repli-
cate pairs, with median Jaccard distances (ranging from 0,
perfect agreement, to 1, absence of overlapping variants; Sup-
plemental Experimental Procedures) of 0.39 (range 0.24–0.64)
for SNVs (Figure 1C) and 0.17 (range 0–0.50) for INDELs (Fig-
ure 1D). Interestingly, the technical replicate pairs with the
highest Jaccard distances were those with the lowest tumor
cell content as inferred by FACETS (Shen and Seshan, 2016)
(Table 1). There were also a small number of potentially patho-
genic variants among the discordant variants in technical repli-
cate pairs (range 0–3; Figure 1C, red bars) that could have
been misinterpreted as ITGH. We obtained fewer somatic muta-
tions but similarly modest reproducibility with the cohort-normal
WES pipeline and far fewer somatic mutations but improved
reproducibility using the tumor-only pipeline (see explanation
below; Figures S1B and S1C). Comparing only the mutations
that were confirmed to be somatic by AmpliSeq between the
technical replicate pairs, we observed almost perfect agreement
for SNVs (Figure 1C) and for INDELs (Figure 1D) (maximum
Jaccard distance of 0.02 and 0, respectively).
When we examined the somatic mutations found to be
concordant or discordant between pairs of technical replicates
on the basis of WES, a median of 95% (range 73%–97%) of
the concordant variants were confirmed to be genuinely somatic
in at least one of the two technical replicates, compared with a
median 33% (range 14%–48%) of the discordant variants (Fig-
ure 1E). Of the discordant WES variants, a median of 44% (range
36%–71%) were found to be absent by AmpliSeq (i.e., false pos-
itive in one of the two technical replicates), and a median of 7%
(range 3%–22%) were germline(-like) variants (i.e., missed by
WES in the matching normal). The validation status of 3% (range
1%–8%) of the mutations could not be ascertained, because of
technical failure of low AmpliSeq coverage in the validation
experiments.
Taken together, these results suggest that WES performed at
typical sequencing depth may be inadequate for detecting
ITGH, particularly when the tumor cell content is less than
50%, as only 62% (range 36%–76%) of the somatic mutations
were detected consistently in the technical replicate pairs
by WES, with the remaining mutations falsely appearing as
discordant.
WES Overestimates True ITGH
Next, we quantified ITGH by comparing somatic variant calls be-
tween the geographically distinct biopsies from the same can-
cer. In this analysis, we also examined how the three different
WES analytic approaches differed in the quantification of ITGH
(Figure S1A; Supplemental Experimental Procedures). Tumor
cellularity of all samples was inferred from WES using FACETS
(Shen and Seshan, 2016) (Table 1). We usedmixed-effects linear
modeling to estimate an average cellularity of 54.7% with intra-
tumor and technical SDs of 7.0% and 2.2%, respectively (Sup-
plemental Experimental Procedures). The matched-normal
pipeline detected a median of 150 unique somatic mutations
(range 68–186) in each tumor. Compared with the matched-
normal pipeline, the cohort-normal pipeline detected a median
of 101 mutations (range 48–131; p > 0.05, Wilcoxon test), and
the tumor-only pipeline identified a median of 62 mutations
(range 36–97; p = 0.01, Wilcoxon test; Figures 2A and 2B;
Table S4).
To assess the reliability of the different WES pipelines in de-
tecting ITGH, we compared the WES candidate mutations with
the ‘‘gold-standard’’ AmpliSeq-validated somatic variants from
the same sample. A median of 62% (range 50%–98%) of the
candidate somatic variants detected by the tumor-only pipeline
were germline variants, and only 28% (range 2%–45%) were
validated as true somatic mutations, highlighting the challenges
posed by this commonly used approach in clinical practice. By
contrast, a median of 79% (range 59%–91%) and 84% (range61%–92%) of the variants defined by the cohort-normal and
the matched-normal pipelines, respectively, were true somatic
mutations (Figures 2A, S1D, and S1E). The tumor-only pipeline
had the lowest sensitivity (median 18%, range 0%–29%) and
precision (median 28%, range 0%–46%) for identifying true so-
matic variants. The matched-normal pipeline had the highest
sensitivity (median 87%, range 47%–94%) and precision (me-
dian 86%, range 62%–94%; Figure 2C), whereas the cohort-
normal pipeline had similar precision (median 83%, range
61%–91%) but significantly lower sensitivity (median 48%, range
26%–64%; p < 0.001,Wilcoxon test). Using thematched-normal
pipeline, tumor cellularity was positively correlated with sensi-
tivity (Pearson r = 0.7, p = 0.001) and numerically, though not
statistically significantly, correlated with precision (Figure S2A).
We did not observe the same correlation with the other two
pipelines.
Next, we estimated the apparent ITGH on the basis of muta-
tions detected by the three WES calling pipelines using the
Jaccard distance as the metric of ITGH. Mutations identified
as somatic in one or two of the three biopsies and as germ-
line-like or absent in the remaining biopsies contributed to
ITGH. The tumor-only pipeline had a median Jaccard distance
of 0.34 (range 0.19–0.96) compared with the cohort-normal
pipeline of 0.70 (range 0.53–0.91) and matched-normal pipeline
of 0.60 (range 0.44–0.89) (Figure 2B). The apparently lower
ITGH defined by the tumor-only pipeline (p = 0.03 for tumor-
only versus cohort-normal, p > 0.05 versus matched-normal,
paired Wilcoxon tests) was due to the large number of germline
variants misidentified as somatic mutations by the tumor-only
pipeline (Figure 2A). When ITGH was estimated on the basis
of the AmpliSeq-validated somatic mutations only, the median
Jaccard distance was 0.40 (range 0.19–0.61; Figure 2B),
which in the context of this study was considered a true esti-
mation of ITGH. We also observed that the proportion of private
mutations in a given biopsy was positively correlated with its
purity relative to the mean purity of all biopsies for the patient
(Pearson r = 0.531, p = 0.023; Figure S2B), suggesting that
ITGH may be overestimated in cases with large variability in tu-
mor purity between biopsies. Compared with the apparent
ITGH defined by the candidate mutations in the cohort-normal
and matched-normal WES pipelines, the true ITGH was signif-
icantly smaller (p = 0.015 versus cohort-normal and p = 0.015
versus matched-normal, paired Wilcoxon tests). We noted
that 5.8% of the heterogeneous variants, also called branch
mutations, that were not present in all biopsies of a given
case were predicted to be pathogenic, but there was no
statistically significant enrichment in pathogenic mutations
compared to non-pathogenic variants among the heteroge-
neous somatic variants (Figure 2B). Heterogeneous variants
were detected in a small number of cancer genes (21 of 306
[6.9%]), and five of these variants (1.6%) were predicted
pathogenic.
Taken together, these results suggest that the tumor-only
WES pipeline misidentifies a substantial proportion of germline
variants as somatic mutations. Even when using the matched-
normal DNA for mutation detection, the extent of ITGH defined
solely on the basis of WES performed at typical sequencing
depth is overestimated, potentially affecting actionable cancerCell Reports 25, 1446–1457, November 6, 2018 1449
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Figure 2. ITGH as Assessed by Different WES Analysis Pipelines
(A) Total number of somatic variants (SNVs and INDELs) identified in intratumor biopsies by the three WES analysis pipelines. One of the two technical replicates
was randomly selected for inclusion in this analysis. Validation status by high-depth amplicon sequencing (i.e., somatic, germline, absent [VAF < 1%], low depth
[< 503 coverage]) is shown according to the color key.
(B) Venn diagrams showing the overlap of putative somatic variants detected in intratumor biopsies from each tumor by the threeWES analysis pipelines. The last
row includes only ‘‘true’’ somatic variants validated by high-depth amplicon sequencing. The size of the circles is proportional to the number of somatic variants in
a biopsy, with the numbers representing the total variants and those in parentheses indicating the number of pathogenic variants.
(C) Performance characteristics of the three WES analysis pipelines to identify true somatic variants. Putative somatic variants were considered as ‘‘true’’ if
confirmed by high-depth amplicon sequencing. Precision was calculated as TP/(FP + TP) and sensitivity as TP/STP, where TP and FP are the number of true-
positive and false-positive variants and STP is the total number of true somatic calls made by all three pipelines. Each circle represents one sample as analyzed by
each pipeline, and the size of the circles is proportional to the number of putative somatic variants per biopsy identified by each analysis pipeline.
See also Figure S2.genes. For example, a deleterious stop-gain branch mutation in
CDC27 (p.Cys71*) was identified as heterogeneous (in one of the
three biopsies) by thematched-normalWES pipeline but was not
validated by AmpliSeq. False-positive heterogeneous variants
were mostly not actionable, however.1450 Cell Reports 25, 1446–1457, November 6, 2018Characteristics of Artifactual WES Somatic Mutations
To identify the characteristics of the putative mutations identified
by WES that were subsequently found not to be truly somatic
variants, we examined the alternative coverage (i.e., the number
of reads supporting the alternate allele), the variant allele
A C
DB
Figure 3. Coverage Characteristics of True Somatic Variants and False-Positive Mutations in the WES Data
(A and B) Alternative allele coverage (i.e., number of read supporting the alternative allele) (A) and total coverage (B) are plotted against variant allele fraction (VAF;
all log10 scale) for the three WES analysis pipelines (rows). The different subsets of WES putative somatic variants according to validation status by high-depth
amplicon sequencing are shown as columns: validated somatic mutations, validated homogeneous somatic mutations (i.e., present in all three biopsies of the
same tumor), validated heterogeneous somatic mutations (i.e., present in one or two biopsies from the same tumor), and putative somatic mutations identified by
theWES pipelines but failed validation by high-depth amplicon sequencing (i.e., putative somaticmutations that were validated to be germline, absent [VAF < 1%]
or low coverage [< 50x]).
(C and D) For the matched-normal WES pipeline, (C) total coverage in the tumor (bottom) is plotted against the coverage in the matched normal sample, and (D)
WES alternative allele coverage is plotted against VAF and of somaticmutations identified in all the specimens. The validation status categories are the same as in
(A) and (B). Density kernel plots of the marginal distributions are included above and to the right of the scatterplots for each of the four categories of mutations.
See also Figure S3.frequency (VAF), and the total depth of coverage of the candi-
date somatic mutations identified by the three WES pipelines
from the intratumor biopsies. The tumor-only pipeline reported
a median of 2 variants (range 0–5) with VAF < 10% because of
reduced sensitivity of the single-sample mutation detection
algorithm at low VAF and the strict filtering imposed to remove
potential germline variants (Figures 3A and 3B). Despite aggres-
sive filtering, most of the putative somatic variants from the
tumor-only analysis were germline variants with VAF  50%,
indicating the presence of a large number of private mutations
that have not been cataloged in publicly available databases
(Figures 2A, 3A, and 3B). The cohort-normal analysis correctly
identified somatic variants with low VAF, including many that
were heterogeneous between the biopsies, but missed somatic
variants with VAF > 45% because of filtering imposed to removelikely germline variants that may not be present in the pooled
normal DNA used as the reference (Figures 2C, 3A, and 3B).
The validated somaticmutations defined by thematched-normal
pipeline covered the widest range of VAFs. The putative somatic
mutations identified by the matched-normal pipeline that were
found to be absent by AmpliSeq were mostly in the low-VAF
range (median 7.3%, range 0.6%–44%; Figures 2A, 3A, and 3B).
Given that the majority of the ITGH studies carried out to date
(Ding et al., 2010; Gerlinger et al., 2012; Nik-Zainal et al., 2012)
used matched tumor-normal samples and analysis pipelines
similar to our matched-normal pipeline and that mainly low-
VAF mutations contributed to ITGH (Figures 3A and 3B), we
compared the true- and false-positive somatic mutations (i.e.,
the validated and the unvalidated putative somatic variants)
and the validated homogeneous (i.e., present in all biopsiesCell Reports 25, 1446–1457, November 6, 2018 1451
from a case) and heterogeneous (i.e., absent in at least one
biopsy from a case) somatic mutations derived from the distinct
biopsies using thematched-normal WES pipeline. We found that
the total depth for the true positive (median 124, range 9–1,028;
Figure 3C, green) was significantly higher than for the false-pos-
itive mutations (median 78, range 12–926; p < 0.001, Wilcoxon
test; Figures 3C and S3A, red). Furthermore, the false positives,
compared with truemutations, had significantly lower alternative
coverage (median 7, range 1–126 versus median 22, range
4–231; p < 0.001, Wilcoxon test) and VAF (median 11%, range
0.6%–64% versus median 23%, range 3%–93%; p < 0.001, Wil-
coxon test; Figures 3D and S3B). There were also significant dif-
ferences in the VAF distribution of the validated homogeneous
and heterogeneous mutations (median 25%, range 1%–93%
versus median 6%, range 1%–57%; p < 0.001, Wilcoxon test)
and between the validated homogeneous mutations and the
false positives (median 25%, range 1%–93% versus median
12%, range 2%–64%; p < 0.001, Wilcoxon test; Figures 3D
and S3B). Crucially, the validated mutations implicated in true
ITGH had significantly lower VAF than the false positives
(p < 0.001, Wilcoxon test; Figures 3D and S3B–S3E), which indi-
cates that true ITGHmutations may display similarly low or lower
VAFs compared with the false-positive and false-negative muta-
tions. These results suggest that filtering somatic variants with
low VAF or low alternative coverage may improve the precision
of the WES pipeline but would also eliminate many true somatic
variants that contribute to ITGH. Importantly, false-positive mu-
tations had significantly lower total depth in the matched normal
DNA (median 35, range 6–492) compared with true-positive mu-
tations (median 68, range 9–514; p < 0.001, Wilcoxon test) and
validated heterogeneous mutations (median 72, range 12–343;
p < 0.001, Wilcoxon test; Figure 3C). Many putative somatic mu-
tations (47%) with total depth in the normal DNA of 10 or less
were confirmed as germline-like by AmpliSeq, emphasizing the
importance of having adequate sequencing depth in the normal
samples.
Separating True ITGH from WES Artifacts
Because subclonal mutations are expected to be the predom-
inant contributors to ITGH, we inferred the clonality of all
mutations identified by WES using ABSOLUTE (Carter et al.,
2012). Subclonal mutations were significantly overrepresented
among the validated heterogeneous variants compared with
the homogeneous somatic variants (83.2% versus 28.9%;
p < 0.001, Fisher’s exact test) but were similarly overrepre-
sented among the artifactual somatic variants (91.5% versus
83.2%; p > 0.05, Fisher’s exact test; Figures 4A and S4A).
Importantly, subclonal mutations were also significantly en-
riched among discordant variants in the WES technical repli-
cates compared with the concordant variants (72.0% versus
24.9%; p < 0.001, Fisher’s exact test; Figures 4A and S4A).
These results suggest that compared with clonal variants, sub-
clonal variants detected by WES are more likely to be errone-
ously attributed to ITGH.
Examination of the genomic locations of mutations revealed
that 41.1% of the artifactual somatic mutations occurred in re-
gions of low mappability (Derrien et al., 2012) compared with
only 6.4% for the validated somatic heterogeneous mutations1452 Cell Reports 25, 1446–1457, November 6, 2018(p < 0.001, Fisher’s exact test; Figures 4B and S4B). Further-
more, 30.8% of the discordant variants in the WES technical
replicates occurred in regions of low mappability compared
with 8.4% for the concordant variants (p < 0.001, Fisher’s
exact test; Figures 4B and S4B). These results suggest that
ambiguous mapping of DNA fragments directly contributes
to artifactual somatic variants, even if longer reads (100 bp)
were used (Figure S4C). Compared with the validated heteroge-
neous mutations, artifactual somatic mutations appeared to be
significantly enriched in T > C transitions (p < 0.001, Fisher’s
exact test; Figures 4C and S5A), particularly in the ApTpA and
NpTpG trinucleotide contexts and also in T > G transversions
in the GpTpG context (Figure 4E). By contrast, artifactual so-
matic mutations were significantly depleted in C > G transver-
sions (p < 0.001, Fisher’s exact test; Figures 4C and S5A).
Interestingly, validated somatic heterogeneous mutations were
enriched for C > G substitutions in the TpCpA and TpCpT con-
texts (Figure 4E), the characteristic substitution patterns induced
by the upregulation of APOBEC cytidine deaminases (Nik-Zainal
et al., 2016). However, this enrichment appears to be driven
primarily by the case with the largest variability in tumor purity
(Figures S2B and S5A). Although a substantial proportion of
the artifactual mutations detected were C > T transitions, which
have been associated with both the aging process and with lab-
induced cytosine deamination during DNA library preparation
(Alexandrov et al., 2013; Chen et al., 2014), their proportion
was similar between the artifactual and validated somatic het-
erogeneous variants (34.6% versus 33.9%; p > 0.05, Fisher’s
exact test; Figure 4C), with mutations occurring in the TpCpN
context being significantly underrepresented in the artifactual
variants (Figure 4E). We also did not observe an enrichment of
C > T substitutions at low VAFs among the artifactual somatic
mutations, which would have been indicative of likely FFPE
fixation artifacts (Graw et al., 2015; Do and Dobrovic, 2015)
(Figure S5B). Mutational signature analysis using previously
defined mutational signatures (Alexandrov et al., 2013) identified
signatures 5 and 29 to be overrepresented in the artifactual
somatic mutations (p = 0.028, Wilcoxon test; Figure 4D), with a
median of 16.1% (range 0%–44.4%) of the artifactual mutations
classified as signature 5, driven mainly by the T > C transitions
reported above. Signature 29 is driven by C > A mutations,
predominantly in the ApCpA and GpCpA contexts, that were
significantly overrepresented among the artifactual variants
(Figure 4E).
Finally, we considered whether applying filtering strategies to
exclude mutations that occur in low-mappability regions or
within sequence contexts enriched in artifactual mutations
(C >Amutations in ApCpA andGpCpA contexts, T >Cmutations
in ApTpA and [C/T/G]pTpG contexts, and T > G mutations in
GpTpG context; Figure 4E) can improve the reliability of WES.
Excluding putative somaticmutations in low-mappability regions
improved the precision for mutations detected in the technical
(0.862 versus 0.792 without filtering) and biological replicates
(0.876 versus 0.817 without filtering), while reducing moderately
the sensitivity (0.858 versus 0.913 for technical, 0.773 versus
0.824 for biological). Filtering by mutational context reduced
the sensitivity without appreciably improving precision, as did
filtering by the combination of filters (Figure 5).
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Figure 4. Mappability and Sequence Context of True and Artifactual Somatic Variants
(A and B) Clonality as defined by ABSOLUTE (A) and mappability of somatic variants (B) identified by the matched-normal WES pipeline. In each panel, the first
two sets of bars enumerate the putative somatic variants identified as concordant or discordant in the technical replicates, whereas the bottom four sets of bars
enumerate the somatic variants identified in intratumor biopsies and subsequently validated by high-depth amplicon sequencing. High-mappability regions are
regions with mappability score of 1 (see Supplemental Experimental Procedures).
(C) Comparison of the mutational spectra of validated somatic heterogeneous mutations and artifactual somatic mutations that failed validation in all samples.
The reference base listed (C or T) includes the corresponding reverse complement (G or A).
(D) Distribution of signature weights obtained from the decomposition of mutational signatures from each tumor sample.
(E) Detailed mutational spectra of the trinucleotide context of the pool of mutations detected in all tumor samples. Trinucleotide contexts with significant
enrichment in the validated somatic heterogeneous mutations or in the artifactual somatic mutations are shown with an asterisk above the corresponding bars.
*p < 0.005. Statistical comparisons in (A), (B), (C), and (E) are based on Fisher’s exact tests. Statistical comparisons in (D) are based on Wilcoxon tests. All
statistical tests are two-sided. A p value < 0.05 was considered to indicate statistical significance. See also Figures S4–S6.
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Figure 5. Effect of Filtering of Variants Called by WES Pipelines in
Technical Replicates and Intratumor Biopsies
Excluding somatic mutations in low-mappability regions improves precision
(or positive predictive value) by reducing false-positive calls, while slightly
reducing the sensitivity by increased false-negative calls.DISCUSSION
WES is an appealing and increasingly affordable technology to
study the extent of ITGH in an unbiased manner (i.e., without a
priori selecting genes of interest for sequencing). The reliability
of WES to detect low-frequency mutations, which often ac-
count for the majority of ITGH within a cancer, and therefore
to resolve clonal architecture (Figure S6) depends on the exper-
imental design, the sequencing depth, tumor purity, and the
bioinformatics approaches used to define the somatic variants.
To examine the influence of these factors on measuring ITGH,
here we generated a dataset incorporating both technical and
biological replicates sequenced to depths commonly found in
clinical or translational research studies, and validated every
putative somatic variant detected with orthogonal high-depth
sequencing methods. All datasets generated in this study
have been made publicly available to provide a resource for
the community to refine analytical tools for ITGH detection
from WES.
We performed six pairs of technical replicates that involved
independent library preparation and sequencing of aliquots
from the same DNA extractions, and experiments were per-
formed on different days. The technical replicates revealed an
unexpectedly high degree of discordance in the putative so-
matic variants identified, even using the current best practice
matched-normal variant calling analysis approach. Subsequent
validation with high-depth amplicon sequencing (6053 median
coverage) of all variants identified by WES demonstrated that
the majority of the false-positive somatic variants (1) displayed
low VAF and were often detected as subclonal in one experi-
ment but not in the other, (2) were in fact germline-like variants
that appeared as heterogeneous somatic mutations (Kim and1454 Cell Reports 25, 1446–1457, November 6, 2018Speed, 2013), or (3) map to genomic regions of low mappabil-
ity. The enrichment of subclonal mutations among the discor-
dant mutations in the WES technical replicates is expected,
given the well-known difficulty in identifying somatic mutations
at low VAF. Indeed, comparing the putative mutations that did
not validate to the ‘‘true’’ somatic mutations validated by high-
depth amplicon sequencing demonstrated that mutations with
low VAF and/or low alternative coverage were more difficult
to be reliably identified by WES. On the other hand, our results
revealed a not insignificant proportion of germline-like false-
positive mutation calls. Although some of these germline-like
variants are genuinely germline alleles not detected in the
matched normal samples, a substantial proportion of these
are likely attributed to alignment and sequencing biases (Kim
and Speed, 2013) that manifested as false-positive variants at
low VAF or alternative coverage. Importantly, our results high-
lighted the often overlooked importance of adequate coverage
for the matched-normal sample in the accurate identification of
somatic mutations, given that mutations that failed validation
were, on average, associated with lower coverage in the normal
sample. In terms of mappability of genomic regions, we found
that false-positive mutation calls were enriched in genomic
regions of poor mappability. In fact, we demonstrated that
this may represent a reasonable filter if specificity is of para-
mount importance and some trade-off in sensitivity can be
tolerated. Although our study provides direct evidence in sup-
port of ITGH, the mutations implicated in ITGH showed sub-
stantial overlap with the alterations stemming from intrinsic
technical noise in terms of VAF, alternate allele depth, total
depth in tumor and normal, as well as mappability. Incorpo-
rating unique molecular identifiers into deep sequencing exper-
iments will likely reduce false positives and enhance sensitivity
in detecting subclonal mutations with greater confidence (Salk
et al., 2018). Furthermore, because private mutations are
less likely to be identified in biopsies of relatively low purity,
ITGH should be best assessed in biopsies with uniformly high
cellularity.
Our analysis of the mutational signatures between the vali-
dated mutations implicated in ITGH versus the false-positive
mutations revealed striking differences. The heterogeneous
mutations were enriched in a pattern typically associated with
increased APOBEC activity, and this pattern has been previ-
ously shown to contribute to ITGH in breast and lung cancers
(de Bruin et al., 2014; Ng et al., 2017). On the other hand,
the false-positive mutations were enriched for, in particular,
C > A and T > G mutations at specific sequence contexts.
A recent study of rare polymorphisms determined by high-
depth whole-genome sequencing in 300 individuals of diverse
genetic origins identified four mutational signatures, two of
which were consistent within populations and had a clear asso-
ciation with geographic distribution (Mathieson and Reich,
2017). The origin of the remaining two were uninterpretable,
with one of these latter signatures dominated by T > G muta-
tions in the GpTpG context and the other signature highly
correlated with COSMIC signature 5, which has been found
in all cancer types (Alexandrov et al., 2013) and has been
suggested to display clock-like properties suggestive of an as-
sociation with the aging process (Alexandrov et al., 2015). Our
analysis of the sequence context of false-positive variants iden-
tified both these features as being significantly enriched in arti-
factual putative mutations (Figures 4C–4E), strongly suggesting
that caution should be exercised in the interpretation of the re-
ported mutational signatures.
This study has several limitations. The sample size of 6 breast
cancers with 18 biopsies may be too limited to allow generalizing
our results on ITGH to all breast cancer subtypes or to other can-
cers. Of note, the unique nested experimental design incorpo-
rating within-sample technical replication, processed and
sequenced in the same manner as the intratumor biopsies, pro-
vided an estimate of background discordance against which the
ITGH results could be interpreted. Additionally, the extensive
orthogonal validation by high-depth amplicon sequencing on
an independent sequencing platform with very different chemis-
try from the platform used for WES adds rigor to our study. The
sequencing depth attained in this study is comparable with that
in previous studies using WES (with subsequent high-depth
sequencing for validation) for the genomic characterization of
ITGH (Yates et al., 2015); it is plausible, however, that WES at
higher depth (i.e., >2503) would mitigate in part the false posi-
tives and false negatives, in particular in samples with tumor
cell content < 50%. Finally, the three WES analyses pipelines
used different calling algorithms and filtering steps that reflected
the best practice at the time of the analysis, but future improve-
ments could result in reduced bias.
In summary, our study showed thatWES at 184mean depth of
coverage in the tumor samples overestimates the extent of
ITGH, and the technical noise associated with somatic mutation
detection using WES alone can confound true ITGH. Our results
also suggested that it is not possible to reduce the false-positive
rate through more aggressive minimum depth filtering without
affecting the sensitivity of detecting true somatic mutations in
the 1%–5% VAF range, but excluding mutations that occur in
low-mappability regions of the genome, or in certain mutational
contexts could reduce artifactual somatic mutations and provide
less biased estimates of ITGH. Nevertheless, orthogonal, high-
depth validation experiments are highly desirable in the context
of quantifying ITGH.EXPERIMENTAL PROCEDURES
Tumor Sample Collection
Breast cancer samples were collected from patients with newly diagnosed
invasive breast cancer with tumor size > 2 cm at the Yale Cancer Center. Tu-
mor tissues were obtained with three punch biopsies at least 1 cm apart from
three different regions of the tumor after pathologic gross examination. Six of
these tumors with high enough cellularity (>50%) and high DNA quality from all
three biopsies and with matched blood DNA were selected for this study.
WES and Analysis
DNA was extracted and library was prepared using standard protocols, and
the exome was captured using the NimbleGen SeqCap EZ Human Exome
Kit version 2.0. Sequencing was performed on the HiSeq 2000 in paired-end
75-cycle mode at the Yale Center for Genome Analysis. We used three
different analytical pipelines for detecting variants. A single-sample ‘‘tumor-
only’’ pipeline, a ‘‘cohort-normal’’ pipeline using an in-house normal reference
obtained from ten unrelated normal blood DNA samples, and a ‘‘matched-
normal’’ pipeline using the matched-normal DNA from each patient as refer-
ence. Further details are provided in Supplemental Experimental Procedures.Validation of Putative Variants with High-Depth Amplicon
Sequencing
Variants identified byWESwere subjected to validation with high-depth ampli-
con sequencing using custom AmpliSeq panels on the same tumor and
matched normal DNA samples. Amplicon sequencing was performed to ame-
dian depth of 6003. Further details are provided in Supplemental Experimental
Procedures.
Mutational Signature Analysis and Mappability
Mutational signature analyses comparing the validated variants that contribute
to ITHG and the WES false-positive calls were performed for individual tumor
samples and for the pooled mutations over all samples using the R package
deconstructSigs (Rosenthal et al., 2016). Mappability of SNVs was assessed
using the CRG Alignability track (Derrien et al., 2012) in the UCSC Genome
Browser. Additional details are provided in Supplemental Experimental
Procedures.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw data from WES and AmpliSeq sequences
reported in this paper is SRA: SRP070662.
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